DOP2010000349A - Heterociclicos que contienen nitrogeno fusionado y composiciones de los mismos como inhibidores de cinasa - Google Patents
Heterociclicos que contienen nitrogeno fusionado y composiciones de los mismos como inhibidores de cinasaInfo
- Publication number
- DOP2010000349A DOP2010000349A DO2010000349A DO2010000349A DOP2010000349A DO P2010000349 A DOP2010000349 A DO P2010000349A DO 2010000349 A DO2010000349 A DO 2010000349A DO 2010000349 A DO2010000349 A DO 2010000349A DO P2010000349 A DOP2010000349 A DO P2010000349A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compositions
- hypercycles
- fusionated
- nitrogen
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
Abstract
La invención proporciona compuestos, composiciones farmacéuticas que comprenden estos compuestos, y métodos para utilizar tales compuestos con el fin de tratar o prevenir las enfermedades o los trastornos asociados con una actividad de cinasa anormal o mal regulada, en particular de Ros, KDR, FMS, c-FMS, FLT3, c-Kit, JAK2, JAK3, Aurora, PDGFR, Lck, TrkA, TrkB, TrkC, IGF-1R, ALK4, ALK5 y ALK, o combinaciones de las mismas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5287908P | 2008-05-13 | 2008-05-13 | |
US15287209P | 2009-02-16 | 2009-02-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2010000349A true DOP2010000349A (es) | 2010-11-30 |
Family
ID=41202804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2010000349A DOP2010000349A (es) | 2008-05-13 | 2010-11-12 | Heterociclicos que contienen nitrogeno fusionado y composiciones de los mismos como inhibidores de cinasa |
Country Status (27)
Country | Link |
---|---|
US (1) | US8507488B2 (es) |
EP (1) | EP2300469B1 (es) |
JP (2) | JP5492194B2 (es) |
KR (1) | KR101324804B1 (es) |
CN (1) | CN102056927B (es) |
AR (1) | AR071778A1 (es) |
AU (1) | AU2009246687B2 (es) |
BR (1) | BRPI0912668A2 (es) |
CA (1) | CA2722418C (es) |
CL (1) | CL2009001160A1 (es) |
CO (1) | CO6321286A2 (es) |
CR (1) | CR11797A (es) |
DO (1) | DOP2010000349A (es) |
EA (1) | EA019507B1 (es) |
EC (1) | ECSP10010676A (es) |
ES (1) | ES2548135T3 (es) |
IL (1) | IL208993A0 (es) |
MA (1) | MA32393B1 (es) |
MX (1) | MX2010012457A (es) |
NI (1) | NI201000194A (es) |
PA (1) | PA8826501A1 (es) |
PE (1) | PE20091849A1 (es) |
SV (1) | SV2010003733A (es) |
TW (1) | TW201012820A (es) |
UY (1) | UY31821A (es) |
WO (1) | WO2009140128A2 (es) |
ZA (1) | ZA201008476B (es) |
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
RS53350B (en) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS |
KR101634833B1 (ko) | 2008-10-22 | 2016-06-29 | 어레이 바이오파마 인크. | TRK 키나아제 억제제로서 치환된 피라졸로[1,5a] 피리미딘 화합물 |
JP5709276B2 (ja) | 2009-04-20 | 2015-04-30 | オースペックス ファーマシューティカルズ,エルエルシー | ヤヌスキナーゼ3のピペリジンインヒビター |
US20110053968A1 (en) | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
JP2013519719A (ja) * | 2010-02-18 | 2013-05-30 | セントロ ナシオナル デ インベスティガシオネス オンコロヒカス(セエネイオ) | トリアゾロ[4,5−b]ピリジン誘導体 |
WO2011112666A1 (en) | 2010-03-09 | 2011-09-15 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
GB201004200D0 (en) * | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
TW201144310A (en) * | 2010-04-28 | 2011-12-16 | Daiichi Sankyo Co Ltd | [5,6] heterocyclic compound |
EP2571878B1 (en) | 2010-05-17 | 2018-10-17 | Incozen Therapeutics Pvt. Ltd. | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases |
EP2918588B1 (en) | 2010-05-20 | 2017-05-03 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
WO2012016133A2 (en) * | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
WO2012034095A1 (en) * | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
UY33597A (es) * | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
ES2543151T3 (es) * | 2010-10-20 | 2015-08-17 | Pfizer Inc | Derivados de 2-piridina como moduladores del receptor Smoothened |
EP2463289A1 (en) * | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
WO2012097478A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Bicyclic carboxamide inhibitors of kinases |
CA2828219A1 (en) * | 2011-02-25 | 2012-08-30 | Irm Llc | Pyrazolo [1,5-a] pyridines as trk inhibitors |
WO2012125667A1 (en) * | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
US8673905B2 (en) * | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
MY173181A (en) | 2011-05-13 | 2020-01-02 | Array Biopharma Inc | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors |
CA2840518A1 (en) * | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
JP6046728B2 (ja) * | 2011-09-30 | 2016-12-21 | オンコデザイン エス.ア. | 大環状flt3キナーゼ阻害剤 |
BR112014014276A2 (pt) | 2011-12-12 | 2017-06-13 | Dr Reddys Laboratories Ltd | composto, composição farmacêutica, método para inibir uma cinase receptora, e, métodos para tratar condições, doenças e/ou distúrbios, e dor |
EP2834243B1 (en) * | 2012-03-09 | 2018-04-25 | Lexicon Pharmaceuticals, Inc. | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE |
DK2822555T3 (en) * | 2012-03-09 | 2018-02-05 | Lexicon Pharmaceuticals Inc | Inhibition of adapter-associated kinase 1 for the treatment of pain |
TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 |
CN104411314B (zh) * | 2012-07-09 | 2017-10-20 | 詹森药业有限公司 | 磷酸二酯酶10的抑制剂 |
US9572811B2 (en) | 2012-08-03 | 2017-02-21 | Principia Biopharma Inc. | Treatment of dry eye |
RS58956B1 (sr) | 2012-09-10 | 2019-08-30 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
CN104640863B (zh) * | 2012-09-20 | 2016-06-08 | 山东亨利医药科技有限责任公司 | 嘧啶胺衍生物及其制备方法和应用 |
KR102156398B1 (ko) | 2012-11-06 | 2020-09-15 | 상하이 포천 파마슈티컬 씨오 엘티디 | Alk 키나아제 억제제 |
WO2014078322A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9809578B2 (en) | 2012-11-13 | 2017-11-07 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors |
WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
HUE031557T2 (en) | 2012-11-13 | 2017-07-28 | Array Biopharma Inc | Bicyclic urea, thiourea, guanidine, and cyanoguadinine compounds used to treat pain |
US9546156B2 (en) | 2012-11-13 | 2017-01-17 | Array Biopharma Inc. | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
UA116455C2 (uk) * | 2012-11-13 | 2018-03-26 | Еррей Біофарма Інк. | Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
CN105164124B (zh) | 2012-11-19 | 2017-03-15 | 诺华股份有限公司 | 用于治疗寄生虫疾病的化合物和组合物 |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
CN105189462B (zh) * | 2013-02-20 | 2017-11-10 | 卡拉制药公司 | 治疗性化合物和其用途 |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
WO2014138692A1 (en) | 2013-03-07 | 2014-09-12 | Califia Bio, Inc. | Mixed lineage kinase inhibitors and method of treatments |
RU2015143526A (ru) * | 2013-03-13 | 2017-04-19 | Бостон Байомедикал, Инк. | Производные 3-(арил или гетероарил)метилениндолин-2-она в качестве ингибиторов киназного пути раковых стволовых клеток для лечения рака |
JP2016510797A (ja) * | 2013-03-15 | 2016-04-11 | オンコデザイン エス.ア. | 大環状塩誘導性キナーゼ阻害剤 |
WO2014178891A1 (en) | 2013-04-30 | 2014-11-06 | Otitopic Inc. | Dry powder formulations and methods of use |
WO2015017528A1 (en) * | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Pik3c2g fusions |
EP3628749A1 (en) * | 2013-07-30 | 2020-04-01 | Blueprint Medicines Corporation | Ntrk2 fusions |
AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
ES2841248T3 (es) | 2014-02-21 | 2021-07-07 | Principia Biopharma Inc | Sales y forma sólida de un inhibidor de BTK |
US10280170B2 (en) | 2014-03-27 | 2019-05-07 | Janssen Pharmaceutica Nv | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors |
EA031639B1 (ru) | 2014-03-27 | 2019-01-31 | Янссен Фармацевтика Нв | ЗАМЕЩЕННЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-а]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ И 2,3-ДИГИДРО-1H-ИМИДАЗО[1,2-b]ПИРАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ROS1 |
CN103864800A (zh) * | 2014-04-03 | 2014-06-18 | 定陶县友帮化工有限公司 | 6-氯咪唑并[1,2-b]哒嗪的合成方法 |
SI3154959T1 (sl) | 2014-05-15 | 2019-10-30 | Array Biopharma Inc | 1-((3S,4R)-4-(3-fluorofenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4- metil-3-(2-metilpirimidin-5-il)-1-fenil-1H-pirazol-5-il)urea kot inhibitor TrkA kinaze |
WO2015183837A1 (en) * | 2014-05-27 | 2015-12-03 | Brian Haynes | Compositions, methods, and uses related to ntrk2-tert fusions |
WO2015183836A1 (en) * | 2014-05-27 | 2015-12-03 | Brian Haynes | Compositions, methods, and uses related to ntrk2-tert fusions |
JP6710642B2 (ja) * | 2014-05-30 | 2020-06-17 | チル ファーマシューティカル カンパニー リミテッド | Hbv阻害剤としてのジヒドロピリミジン縮環誘導体 |
JP6602834B2 (ja) | 2014-06-30 | 2019-11-06 | ターベダ セラピューティクス インコーポレイテッド | 標的化コンジュゲートならびにその粒子及び製剤 |
CA3005158A1 (en) * | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
DK3699181T3 (da) | 2014-11-16 | 2023-03-20 | Array Biopharma Inc | Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat |
CA2971024C (en) | 2014-12-15 | 2023-09-26 | Handok Inc. | Fused ring heteroaryl compounds and their use as trk inhibitors |
PT3233103T (pt) | 2014-12-18 | 2021-01-18 | Principia Biopharma Inc | Tratamento de pênfigo |
MA42242A (fr) | 2015-06-24 | 2018-05-02 | Principia Biopharma Inc | Inhibiteurs de la tyrosine kinase |
AU2016287581B2 (en) | 2015-07-02 | 2019-06-06 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
BR112018008357A2 (pt) | 2015-10-26 | 2018-11-27 | Array Biopharma Inc | mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas |
WO2017075495A1 (en) | 2015-10-28 | 2017-05-04 | Tarveda Therapeutics, Inc. | Sstr-targeted conjugates and particles and formulations thereof |
RU2751767C2 (ru) | 2016-04-04 | 2021-07-16 | Локсо Онколоджи, Инк. | Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
LT3458456T (lt) | 2016-05-18 | 2021-02-25 | Loxo Oncology, Inc. | (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamido gavimas |
KR102515813B1 (ko) | 2016-06-29 | 2023-03-30 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 변형 방출 제제 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
CN109890820B (zh) * | 2016-10-28 | 2020-11-03 | 正大天晴药业集团股份有限公司 | 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物 |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
KR20230040375A (ko) | 2017-09-22 | 2023-03-22 | 오티토픽 인코퍼레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
LT3724191T (lt) | 2017-12-15 | 2022-04-25 | Pyramid Biosciences, Inc. | 5-(2-(2,5-difluorofenil)pirolidin-1-il)-3-(1h-pirazol-1-il)pirazol[1,5-a]pirimidino dariniai ir susiję junginiai kaip trk kinazės inhibitoriai, skirti vėžiui gydyti |
US20200171030A1 (en) * | 2018-01-18 | 2020-06-04 | Integral Biosciences Private Limited | Dual inhibitors of alk5 and p38a map kinase |
CN108218754B (zh) * | 2018-01-23 | 2021-05-07 | 广东赛烽医药科技有限公司 | 一种2-(2,5-二氟苯基)吡咯烷的制备方法 |
TWI816742B (zh) * | 2018-01-29 | 2023-10-01 | 美商維泰克斯製藥公司 | Gcn2抑制劑及其用途 |
WO2019169249A1 (en) * | 2018-03-01 | 2019-09-06 | The Johns Hopkins University | INHIBITION OF nSMase FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION |
KR20200141035A (ko) * | 2018-03-14 | 2020-12-17 | 포천 파마슈티컬즈, 엘티디. | TRK 키나제 억제제로서의 치환된 (2-아자비사이클로 [3.1.0] 헥산-2-일) 피라졸로 [1, 5-a] 피리미딘 및 이미다조 [1, 2-b] 피리다진 화합물 |
WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
GB201811825D0 (en) * | 2018-07-19 | 2018-09-05 | Benevolentai Bio Ltd | Organic compounds |
CN110790739B (zh) * | 2018-08-01 | 2021-10-01 | 陕西麦科奥特科技有限公司 | 用于治疗神经系统疾病的化合物及其应用 |
US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
CN111039946A (zh) * | 2018-10-15 | 2020-04-21 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
CN111302995A (zh) * | 2018-12-12 | 2020-06-19 | 上海复星星泰医药科技有限公司 | 一种2-(2,5-二氟苯基)-吡咯烷消旋体的制备方法 |
CN109942582B (zh) * | 2019-03-15 | 2020-12-01 | 上海健康医学院 | 一种靶向原肌球蛋白激酶trk融合蛋白的pet探针及其合成与应用 |
JP2022532145A (ja) * | 2019-05-09 | 2022-07-13 | ブリストル-マイヤーズ スクイブ カンパニー | 置換ベンズイミダゾロン化合物 |
CN112142731B (zh) * | 2019-06-28 | 2022-07-22 | 成都赜灵生物医药科技有限公司 | 一种2,4-二取代嘧啶衍生物及其制备方法和用途 |
WO2021038419A1 (en) * | 2019-08-23 | 2021-03-04 | Insilico Medicine Ip Limited | Kinase inhibitors and methods of synthesis and treatment |
WO2021047584A1 (en) * | 2019-09-11 | 2021-03-18 | Fochon Pharmaceuticals, Ltd. | SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS |
WO2021067749A2 (en) * | 2019-10-02 | 2021-04-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the treatment of osteoarthritis |
MX2022008930A (es) * | 2020-01-22 | 2022-10-18 | Benevolentai Bio Ltd | Composiciones farmaceuticas y sus usos. |
CN111393347B (zh) * | 2020-04-30 | 2020-11-17 | 安徽德信佳生物医药有限公司 | 一种拉洛替尼中间体的合成方法 |
CN114315900B (zh) * | 2020-09-30 | 2023-09-05 | 美迪西普胜医药科技(上海)有限公司 | 3-芳基吡唑并嘧啶类衍生物及其应用 |
IL303709A (en) * | 2020-12-15 | 2023-08-01 | Childrens Hospital Med Ct | IRAK and FLT3 inhibitory multicyclic compounds and their uses |
WO2022268080A1 (zh) * | 2021-06-21 | 2022-12-29 | 河南迈英诺医药科技有限公司 | Trk激酶抑制剂化合物及其用途 |
WO2023272701A1 (en) * | 2021-07-01 | 2023-01-05 | Anheart Therapeutics (Hangzhou) Co., Ltd. | Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof |
CN113480543B (zh) * | 2021-07-07 | 2022-05-17 | 无锡市第二人民医院 | 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用 |
CN113564121A (zh) * | 2021-08-10 | 2021-10-29 | 合肥滴碧云生物科技有限公司 | 一种造血干细胞冻存方法 |
WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
WO2023245123A2 (en) * | 2022-06-15 | 2023-12-21 | Children's Hospital Medical Center | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof |
WO2024054512A1 (en) * | 2022-09-08 | 2024-03-14 | Alterome Therapeutics, Inc. | Akt1 modulators |
US20240124450A1 (en) * | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5636900A (en) * | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
US6316444B1 (en) * | 1999-06-30 | 2001-11-13 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
ATE311385T1 (de) * | 1999-10-27 | 2005-12-15 | Novartis Pharma Gmbh | Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika |
US7306631B2 (en) * | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
US8030327B2 (en) * | 2004-11-08 | 2011-10-04 | Mds K.K. | Fused imidazole derivative |
US20100216798A1 (en) * | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
US20070049591A1 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US7723336B2 (en) * | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
EP2058309A4 (en) * | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
EP2063962A2 (en) * | 2006-09-07 | 2009-06-03 | Biogen Idec MA Inc. | Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
AU2007302263A1 (en) * | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as P13K lipid kinase inhibitors |
WO2008052734A1 (en) * | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
AR064420A1 (es) * | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
RS53350B (en) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS |
-
2009
- 2009-05-07 WO PCT/US2009/043073 patent/WO2009140128A2/en active Application Filing
- 2009-05-07 BR BRPI0912668A patent/BRPI0912668A2/pt not_active IP Right Cessation
- 2009-05-07 ES ES09747213.8T patent/ES2548135T3/es active Active
- 2009-05-07 JP JP2011509564A patent/JP5492194B2/ja not_active Expired - Fee Related
- 2009-05-07 CA CA2722418A patent/CA2722418C/en not_active Expired - Fee Related
- 2009-05-07 CN CN200980121828.XA patent/CN102056927B/zh not_active Expired - Fee Related
- 2009-05-07 KR KR1020107027784A patent/KR101324804B1/ko not_active IP Right Cessation
- 2009-05-07 US US12/992,027 patent/US8507488B2/en active Active
- 2009-05-07 AU AU2009246687A patent/AU2009246687B2/en not_active Ceased
- 2009-05-07 EA EA201001774A patent/EA019507B1/ru not_active IP Right Cessation
- 2009-05-07 EP EP09747213.8A patent/EP2300469B1/en active Active
- 2009-05-07 MX MX2010012457A patent/MX2010012457A/es active IP Right Grant
- 2009-05-12 UY UY0001031821A patent/UY31821A/es not_active Application Discontinuation
- 2009-05-13 TW TW098115907A patent/TW201012820A/zh unknown
- 2009-05-13 AR ARP090101724A patent/AR071778A1/es unknown
- 2009-05-13 PE PE2009000671A patent/PE20091849A1/es not_active Application Discontinuation
- 2009-05-13 PA PA20098826501A patent/PA8826501A1/es unknown
- 2009-05-13 CL CL2009001160A patent/CL2009001160A1/es unknown
-
2010
- 2010-10-28 IL IL208993A patent/IL208993A0/en unknown
- 2010-11-12 SV SV2010003733A patent/SV2010003733A/es not_active Application Discontinuation
- 2010-11-12 NI NI201000194A patent/NI201000194A/es unknown
- 2010-11-12 DO DO2010000349A patent/DOP2010000349A/es unknown
- 2010-11-18 CR CR11797A patent/CR11797A/es not_active Application Discontinuation
- 2010-11-25 ZA ZA2010/08476A patent/ZA201008476B/en unknown
- 2010-12-06 CO CO10153711A patent/CO6321286A2/es not_active Application Discontinuation
- 2010-12-10 MA MA33422A patent/MA32393B1/fr unknown
- 2010-12-13 EC EC2010010676A patent/ECSP10010676A/es unknown
-
2014
- 2014-01-29 JP JP2014014101A patent/JP2014098010A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2010000349A (es) | Heterociclicos que contienen nitrogeno fusionado y composiciones de los mismos como inhibidores de cinasa | |
UY31624A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
ECSP12011700A (es) | Compuestos y composiciones como inhibidores de cinasa de proteína | |
GT201400036A (es) | Compuestos y composiciones como inhibidores de la quinasa c - kit | |
PA8675701A1 (es) | Nuevos derivados del fluoreno, composiciones que los contienen y su utilización | |
NI201100166A (es) | Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa | |
UY33346A (es) | Compuestos y metodos para la modulacion de quinasa e indicaciones de la misma | |
ECSP109957A (es) | Derivados de pirimidinil-piridazinona. | |
UY28876A1 (es) | Compuestos de morfolina sustituida y composiciones para el tratamiento de trastornos del sistema nervioso central | |
UY32123A (es) | Derivados de n - (sustituido) - 4 - (but-2-iniloxi) - benzamida, sus racematos, diastereòmeros, enantiòmeros y las sales de los mismos y aplicaciones | |
UY31860A (es) | Piridinas de tiazolo como inhibidoras de la adn girasa | |
EA200900783A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
CO7091174A2 (es) | Compuestos triazolo como inhibidores de pde10 | |
CL2018001085A1 (es) | Derivados de indolin-2-ona | |
UY35685A (es) | Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso | |
PE20150965A1 (es) | Azaindolinas | |
EA201100615A1 (ru) | Производные салициловой кислоты в качестве ингибиторов активности фарнезилпирофосфатсинтазы | |
UY33535A (es) | Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona | |
CU20100220A7 (es) | Heterociclos que contienen nitrógeno fusionado y composiciones de los mismos como inhibidores de cinasa | |
SV2011003821A (es) | Compuestos de fenantrenona, composiciones y metodos | |
UY29052A1 (es) | Nuevos inhibidores de la recaptación de norepinefrina de quinoxalinona para el tratamiento de trastornos del sistema nervioso central | |
SV2006001934A (es) | Derivados de morfolina como inhibidores de la recaptacion de norepinefrina ref. x-15830 | |
ECSP099644A (es) | Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico | |
TN2010000519A1 (en) | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |